[Do Turkish reimbursement recommendations cover current European Lipid Guidelines? A retrospective analysis of patients presenting with first acute coronary syndrom]

Autor: Murat Esin, Duygu Ersan Demirci, Özkan Kayhan, Şakir Arslan, Deniz Demirci
Rok vydání: 2017
Předmět:
Adult
Male
lcsh:Internal medicine
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_specialty
Acute coronary syndrome
statin treatment
Turkey
european society of cardiology guidelines
health implementation directive
lcsh:Medicine
Hyperlipidemias
Diabetes Complications
Internal medicine
Diabetes mellitus
Hyperlipidemia
medicine
hyperlipidemia
Humans
Acute Coronary Syndrome
lcsh:RC31-1245
Reimbursement
Aged
Retrospective Studies
Aged
80 and over
business.industry
lcsh:R
Age Factors
Retrospective cohort study
Cholesterol
LDL
Statin treatment
Middle Aged
medicine.disease
Primary Prevention
Stenosis
lcsh:RC666-701
embryonic structures
Insurance
Health
Reimbursement
Practice Guidelines as Topic
Physical therapy
Female
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiology and Cardiovascular Medicine
Risk assessment
business
Zdroj: Türk Kardiyoloji Derneği Arşivi, Vol 45, Iss 7, Pp 623-629 (2017)
ISSN: 1308-4488
Popis: Objective: This study was a comparison of the statin therapy protocol issued by the European Society of Cardiology (ESC) and the Ministry of Health's Health Implementation Directive (SUT) in Turkey, performed in order to assess the adequacy of hyperlipidemia treatment indications for primary prevention. Methods: A total of 582 patients with first acute coronary syndrome were included in the study. Patients with noncritical stenosis observed on coronary angiography or a history of atherosclerotic disease were excluded. The risk calculation was determined using age, sex, smoking status, presence of diabetes mellitus, total cholesterol, and lipoprotein levels. Statin treatment indications were evaluated according to the ESC guidelines (2016) and the SUT (2016). Results: Statin treatment was indicated for 96% of diabetic patients, and according to the ESC, it was appropriate for 13.5% of nondiabetic patients, while the SUT recommendation included 13.3% of nondiabetic patients (p190 mg/dL there was greater discrepancy between the SUT and ESC guidelines. According to the SUT, all patients >190 mg/dL are to receive treatment. The ESC had more guidelines than the SUT for cases of LDL-C 60 years of age and those with LDL-C >160 mg/dL should be reassessed, as they are more limited than those of the ESC. A new treatment algorithm should be defined.
Databáze: OpenAIRE
Externí odkaz: